## Gene Summary
The gene GCG stands for glucagon, which plays a crucial role in carbohydrate metabolism by increasing blood glucose levels through the promotion of glycogenolysis and gluconeogenesis. This gene is primarily expressed in the pancreatic alpha cells, where it serves as a counter-regulatory hormone to insulin. GCG encodes a preproprotein that is processed to yield several products including glucagon, glucagon-like peptides (GLPs), and other biologically active peptides. These peptides are involved in glucose metabolism as well as gastrointestinal functions.

## Gene Drugs, Diseases, Phenotypes, and Pathways
Glucagon, produced by the GCG gene, is directly utilized as a medicinal drug in the form of glucagon injection, primarily used to treat severe hypoglycemia. Disorders associated with the GCG gene include conditions like hyperglucagonemia and glucagonoma, a rare form of pancreatic neuroendocrine tumor characterized by the overproduction of glucagon. Additionally, variants and expression changes in GCG can influence diabetic phenotypes, including type 2 diabetes mellitus. The gene is part of critical pathways such as the metabolism of proteins, peptide hormone metabolism, and plays a significant role in the glucose homeostasis pathway.

## Pharmacogenetics
The pharmacogenetics of the GCG gene primarily revolves around its product's use in glucagon emergency treatment therapies for hypoglycemia, typically in diabetic patients. Variations in the GCG gene can influence the individual response to glucagon treatment, impacting the efficacy and kinetics of glucose level recovery. Research into the gene's polymorphisms may lead to more personalized and effective management strategies for hypoglycemia and other glucose-related disorders. Understanding these genetic variations is crucial for optimizing glucagon use, minimizing side effects, and tailoring treatments to individual genetic profiles.